Exhibit 99.1
Adagio Therapeutics Announces Expansion of Management Team and Board of Directors
to Support Rapid Advancement and Commercial Readiness of ADG20 for COVID-19
Waltham, MA – Nov. 22, 2021 – Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that Jill Andersen has been appointed as chief legal officer, bringing over 20 years of legal, compliance and leadership experience in the pharmaceutical industry, government and private practice. In addition, Redonda Miller, M.D., MBA, president of The Johns Hopkins Hospital, and Ellen Marram, an experienced corporate director and board leader, and the former CEO of several consumer product companies, have joined Adagio’s board of directors.
“We are thrilled to expand our executive team and welcome Jill as our chief legal officer,” said Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio. “The key focus at Adagio today is our rapid advancement of ADG20 through two global clinical trials toward a potential emergency use authorization and ultimately, a full approval, as we work to combat the ongoing COVID-19 pandemic. Jill has tremendous experience and a proven track record across a variety of legal functions within the pharmaceutical industry, including leading through a recent FDA approval and product launch. Her counsel and expertise will be instrumental in our regulatory and corporate execution going forward.”
Rene Russo, co-founder and chairman of Adagio’s board of directors commented, “Adagio’s commitment to advancing a potent and broadly neutralizing therapeutic to address the COVID-19 pandemic is unparalleled, and it’s critical that we have a strong team to guide both clinical development and the anticipated future commercialization. The additions of Redonda and Ellen to the Adagio board complement the company’s experienced and seasoned leadership team and board. As the leader of one of the nation’s top hospitals, Redonda provides a valuable patient perspective and key insights into the clinical advancement of compelling medicines, particularly having been on the front lines throughout the COVID-19 pandemic. Ellen brings a unique viewpoint as a proven business leader who has led many organizations and built dozens of profitable consumer brands, many of which address consumer health concerns. We look forward to partnering with them in an effort to deliver much-needed prophylactic and therapeutic options for this ongoing crisis.”
Ms. Jill Andersen
Ms. Andersen joins Adagio from Oyster Point Pharma where she served as general counsel, corporate secretary and chief compliance officer, and recently led and supported critical components of the company’s first FDA approval and product launch. Prior to that, she was with Bristol Myers Squibb, following the Celgene acquisition, and served as vice president, head of legal for the inflammation & immunology global franchise. Prior to joining Celgene, she held positions of increasing responsibility at Novartis, including senior leadership roles in legal and compliance at Novartis Pharmaceuticals Corporation, Novartis Consumer Health and Novartis Services. Ms. Andersen has worked extensively on matters related to product development, marketing approval and commercialization, including product launches across multiple therapeutic areas. Her experience also spans corporate governance, securities, corporate transactions, IP, litigation and investigations. Prior to joining the pharmaceutical industry, she was an Assistant U.S. Attorney for the District of New Jersey and was a litigation associate at the law firm of Davis Polk & Wardwell. She holds a J.D. from Wake Forest University, School of Law and a B.S. in finance from Boston College.
1
